[1] Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine,2009,27（47）:6550-6557.
[2] Gen-Probe Inc. Procleix Ultrio Plus Package Insert. 503644 EN Rev. A. San Diego, CA, Gen-Probe Inc, 2012.
[3] Tsoi WC, Lelie N,Lin CK. Enhanced detection of hepatitis B virus in Hong Kong blood donors after introduction of a more sensitive transcription-mediated amplification assay[J]. Transfusion,2013,53 (Suppl. 3): 2477-2488.
[4] Taira R, Satake M, Momose S, et al. Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan[J]. Transfusion,2013,53（7）:1393-1404.
[5] Yang Z, Xu L, Liu L, et al. Routine screening of blood donations at Qingdao central blood bank, China, for hepatitis B virus (HBV) DNA with a real-time, multiplex nucleic acid test for HBV, hepatitis C virus, and human immunodeficiency virus Types 1 and 2[J]. Transfusion,2013,53 (Suppl.3): 2538-2544.
[6] Charlewood R,Flanagan P. Ultrio and Ultrio Plus non-discriminating reactives: false reactives or not?[J]. Vox Sang,2013,104（1）:7-111.
[7] 郑优荣,梁浩坚,李仲平,等.核酸检测技术在广州地区献血者血液筛查中的应用[J].中国输血杂志,2013, 26(12):1211-1214.
[8] Grabarczyk P, van Drimmelen H, Kopacz A, et al. Head-to-head comparison of two transcription-mediated amplification assay versions for detection of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus Type 1 in blood donors[J]. Transfusion,2013,53(Suppl. 3):2512-2524.
[9] Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, et al. Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients[J]. J Hepatol,2008,48（6）:1022-1025.
[10] Candotti D, Lin CK, Belkhiri D,et al. Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence[J]. Gut,2012,61（12）:1744-1753.
[11] Weusten J, Vermeulen M, van Drimmelen H, et al. Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms[J]. Transfusion,2011,51（1）: 203-215.
[12] Vermeulen M, Coleman C, Mitchel J, et al. A Mathematical Approach to determine efficacy of NAT in removing Transmission risk of occult HBV infection by blood components[J]. Vox Sang, 2012,103 (Suppl. 1):18-19.
[13] U. S. Food and Drug Administration: Guidance for Industry. Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components, including Source Plasma, to Reduce the Risk of Transmission of Hepatitis B Virus. 2012.
[14] 谢云铮,陈凌燕,李超,等. 上海地区无偿献血者乙肝病毒核酸检测分析[J]. 中国输血杂志, 2012, 25(8): 738-741. |
